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Abstract
Objectives—To determine the prevalence of pre-frailty among HIV-infected persons and 
associations with pre-frailty and frailty in this population.
Design, Setting and Participants—From a contemporary, prospective observational cohort of 
HIV-infected persons (SUN Study), we determined, using a cross-sectional analytic study design, 
the proportions of non-frail, pre-frail, and frail persons by the respective presence of 0, 1-2, and ≥ 
3 of 5 established frailty criteria: unintentional weight loss, exhaustion, physical-inactivity, weak-
grip and slow-walk. We evaluated associations with pre-frailty/frailty using multivariate analysis.
Results—Of 322 participants assessed (79% men, 58% white non-Hispanic, median age 47 
years, 95% on combination antiretroviral therapy [cART], median CD4 + cell count 641 
cells/mm3 and 93% HIV RNA < 400 copies/mL), 57% were non-frail, 38% pre-frail, and 5% frail. 
Age increased from non-frailty through frailty. Notably, however, half of pre-frail and frail 
participants were < 50 years, and of those, 42% and 100%, respectively, were long-term 
unemployed (versus 16% of non-frail counterparts). In multivariate analysis, pre-frail/frail 
participants were more likely to have Hepatitis C seropositivity (adjusted odds ratio [aOR] 3.24, 
95% CI: 1.35-7.78), a history of AIDS-defining-illness (aOR 3.51, 95% CI: 1.82-6.76), greater 
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depressive symptoms (aOR 1.16, 95% CI:1.09-1.23), higher D-dimer levels (aOR 2.94, 95% CI:
1.10-7.87), and were less likely to be white non-Hispanic (aOR 0.35, 95% CI: 0.20-0.61).
Conclusions—Pre-frailty and frailty are prevalent in the cART era and are associated with 
unemployment even among persons < 50 years. Pre-frailty appears to be an intermediate state in 
the spectrum from non-frailty through frailty and our characterization of pre-frailty/frailty suggests 
complex multifactorial associations.
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Introduction
Frailty is a state of diminished reserve and increased vulnerability due to an accumulation of 
deficits in multiple physiological domains (1). It is characterized by weight loss, exhaustion, 
physical inactivity, reduced muscle strength, and slowed motor function but medical and 
psychosocial comorbidity are also evident (1-6).
Immunodeficiency is associated with HIV-related frailty (6-8), and to higher levels of 
markers of monocyte/macrophage and T-cell activation (9). The additional contributions of 
coagulopathy and endocrine dysfunction, as seen in age-related frailty (10, 11), remain to be 
elucidated.
Lastly, frailty among older HIV-uninfected persons is typically preceded by a subclinical 
pre-frail state that transitions to frailty once a threshold of physiological dysregulation is 
reached (3). However, the prevalence and significance of pre-frailty among HIV-infected 
populations is not well-described. We evaluated the prevalence of non-frailty, pre-frailty, and 
frailty among HIV-infected participants in the SUN Study (Study to Understand the Natural 
History of HIV and AIDS in the Era of Effective Therapy) and examined associations of 




The SUN Study is a closed, prospective, observational cohort study funded by the Centers 
for Disease Control and Prevention (CDC) that monitored the clinical course of persons in 
the combination antiretroviral therapy (cART) era at seven HIV-specialty clinics in four US 
cities: St. Louis, MO; Providence, RI; Minneapolis, MN; and Denver, CO. Seven hundred 
HIV-infected participants were enrolled between March 1, 2004 and June 30, 2006. The 
study's design and methods have been described previously (12). Participants were generally 
healthy adults receiving routine outpatient care and were either treatment naïve, or had only 
received combination antiretroviral therapy (cART). Participant data were abstracted from 
medical charts and entered into an electronic database (Clinical Practice Analyst; Cerner 
Corporation, Vienna, VA) by trained staff.
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Additional data were collected through biannual study visits and included comprehensive 
testing for sexually transmitted diseases (STD), and an audio computer-assisted interview 
about health-related information; tobacco, alcohol, and recreational drug use, assessment of 
depression (PRIME MD depression screener) and general function (Short Form 12 [SF-12]) 
(12)). The study protocol was approved and annually reviewed by the CDC and participating 
sites′ institutional review boards.
Frailty assessment
Frailty assessments, using a well-validated and applied frailty appraisal as devised by Fried 
et al. (1), were incorporated into the SUN Study in June 2010 and prospectively conducted 
bi-annually thereafter. Only initial frailty assessment data from June 2010 to April 2011 
were used for this analysis. The frailty assessment took a few minutes to perform by trained 
study coordinators. Non-frailty, pre-frailty, and frailty were defined by the presence of 0, 
1-2, and ≥ 3 of 5 frailty criteria, respectively: unintentional weight loss, physical inactivity, 
exhaustion, weak grip strength, and slow walk, with modification to accommodate physical 
inactivity (Table 2).
Data and definitions
Data collected at the time of initial frailty assessment and retrospectively through study 
enrollment were used. Data at initial frailty assessment included, race/ethnicity (white non-
Hispanic versus [vs.] all others), employment status (fulltime/part-time employed vs. 
unemployed), tobacco use (ever/current vs. never), and recent (past 30 days) alcohol use, as 
well as the number of days per month in which alcohol was consumed. Long-term 
unemplyment and long-term alcohol use were defined as reports of unemployment and 
recent alcohol use at ≥ 75% of previous visits, respectively.
The variable for ‘past depression score’ was calculated as the median of all scores from 
PRIME MD at previous study visits. ‘Current depression score’ was the score from PRIME 
MD at initial frailty assessment. Similar assessments were made for statements of perceived 
general health and past health limitations to moderate activities using the SF-12 (12). ‘Past 
physical inactivity’ was present if the median response to past health limitations to moderate 
activities was “limited a lot“.
HIV-related data included history of AIDS-defining opportunistic illnesses (ADI), and 
cART, CD4+ cell count and HIV viral load history. A plasma HIV RNA concentration of < 
400 copies/mL defined viral suppression. Hepatitis C seropositivity defined hepatitis C 
infection, and detectable serum surface antigen defined active hepatitis B infection. A body 
mass index (BMI) ≥ 30 kg/m2 defined obesity and a BMI < 18.5 kg/m2 defined underweight. 
Chronic kidney disease was defined as a glomerular filtration rate (eGFR) < 60 ml/min/
1.73m2 calculated using Modification of Diet in Renal Disease (MDRD) formula. The 
Diabetes Research and Training Center Radioimmunoassay Core Laboratory (Washington 
University School of Medicine) used stored serum and plasma collected at study entry from 
all participants to assay select biomarker levels retrospectively. Serum and plasma used for 
these assays were iced, centrifuged, and stored at –70°C within 24 hours of collection until 
time of batched assay. We assayed for the following biomarkers: high sensitivity C-reactive 
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protein (hs-CRP), interleukin-1 (IL-1), IL-6, tumor necrosis factor-α (TNF-α), 25-
hydroxyvitamin D, D-dimer, soluble CD-14, and lipoprotein A.
Statistical analysis
Univariate analyses—Descriptive statistics were used to compare characteristics between 
non-frail, pre-frail and frail groups. Associations between non-frailty, pre-frailty, and frailty 
were assessed using the chi-square test for categorical variables; a p-value of < 0.001 was 
considered significant using the Bonferroni correction. For normally distributed and non-
normally distributed continuous variables, one-way analysis of variance and the Kruskal-
Wallis tests were used, respectively; a p-value of < 0.05 was considered significant for these 
tests.
Multivariate analyses—Pre-frail and frail categories were collapsed into one outcome to 
evaluate factors independently associated with pre-frailty/frailty. Categorical variables were 
analyzed using chi square. For normally distributed and non-normally distributed continuous 
variables, student t-test and Mann-Whitney test were used, respectively. In order to generate 
odds ratios (OR) for each continuous variable, all were analyzed individually using logistic 
regression. Using clinically relevant cut-points, where possible, D-dimer was categorized by 
a cut-point of > 0.34 µg/mL (13), hsCRP by a cut-point of > 3.00 mg/L (14) and 25 
hydroxyvitamin D levels by a cut-point of < 30 ng/mL (15). The upper quartile levels of 
TNF-α, sCD14 and lipoprotein A were calculated for all persons and the respective values 
used as cut-points to calculate the OR categorized by upper quartile vs. the lower quartiles. 
Cut-points of 200 cells/mm3 and 350 cells/mm3 were used to categorize nadir and current 
CD4+ counts, respectively. All variables associated with pre-frailty/frailty at p < 0.10 in 
univariate analyses were initially included in a multivariate logistic regression model. 
Variables which were non-significant in the multivariable model (p > 0.05) were then 
eliminated and the model re-fit. The Hosmer-Lemeshow test was used to assess the model's 
calibration (goodness of fit). All analyses were performed using SPSS version 20.0 
(Chicago, IL).
Results
Overall, 346 SUN participants underwent a frailty assessment, however, 24 (7%) 
participants were excluded from analysis due to missing components of the assessment; all 
had no positive frailty criteria and exact frailty status could not be ascertained. Ten 
additional participants also had missing components of the assessment but had 1-2 frailty 
criteria present. This latter group was included for analysis of the pre-frail/frail group vs. the 
non-frail group and their characteristics are also presented below.
Therefore of 322 (93%) participants with sufficient data for study analysis; 79% were men, 
58% were white non-Hispanic with median age 47 years, 24% had a history of ADI, current 
median CD4+ cell count was 641 cells/mm3, 95% were taking cART, and 93% were 
virologically suppressed (Table 1).
In total, 176 (57%) participants were non-frail and 146 (43%) had ≥ 1 frailty criteria present. 
Excluding the ten participants mentioned above; 121 (38%) participants were definitively 
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defined as pre-frail, and 15 (5%) as frail. Most participants were categorized as pre-frail by 
exhaustion (63%), then physical inactivity (29%). Most persons were categorized as frail by 
physical inactivity (100%), exhaustion (73%), and weak grip strength (73%) (Table 2). Of 
note, current depression scores were greater among participants who reported physical 
inactivity, median 8 (4-13) vs. no physical inactivity 3 (1-7), or exhaustion, median 7 (3-11) 
vs. no exhaustion 3 (1-6); both p < 0.001. Age increased from non-frailty through frailty 
(Table 1), although half of pre-frail (67/121) and frail (7/15) participants were < 50 years of 
age (Figure 1). Notably, 42% of pre-frail and 100% of frail participants < 50 years of age 
were long-term unemployed compared with 16% of non-frail ones. Findings were similar for 
current unemployment. Lastly, 53% of frail participants perceived their current general 
health to be either fair or poor compared with 26% of pre-frail and 6% of non-frail 
participants (p < 0.001). Furthermore, 47% of frail participants reported past physical 
inactivity compared with 7% of pre-frail and 1% of non-frail ones, (p < 0.001).
Compared with non-frail participants, pre-frail/frail participants had lower odds of being 
white non-Hispanic (aOR 0.35, 95%CI: 0.20-0.61), higher odds of hepatitis C seropositivity 
(aOR 3.24, 95% CI: 1.35-7.78), and higher odds of history of ADI (aOR 3.51, 95% CI: 
1.82-6.76) (Table 3). Current depression scores were greater (aOR 1.16, 95% CI: 1.09-1.23) 
and D-dimer levels were higher (aOR 2.94, 95% CI: 1.10-7.87).
Current CD4+ cell counts and the proportion of participants with viral suppression were 
comparable between groups. A sub-analysis of participants (n = 203) with full viral 
suppression on cART, demonstrated similar associations excluding hepatitis C seropositivity 
(results not shown).
Discussion
Among our contemporary cohort of predominantly middle-aged participants with well-
controlled HIV infection and high median CD4+ cell counts, we demonstrated a prevalence 
of frailty of 5%. This was comparable to the lower prevalence reported among similarly 
aged HIV-infected cohorts (6-8) and among HIV-uninfected persons in their 7th decade of 
life (1, 3-5, 7, 16). Our pre-frailty prevalence of 38% was comparable to estimates reported 
among older HIV-uninfected persons (28-51%) (4, 7). Furthermore, half of pre-frail and frail 
participants in our study were < 50 years of age, a concerning finding given the many co-
morbidities that affect HIV-infected persons as they age (17) and the higher mortality risk 
associated with pre-frailty/frailty as determined by the Veterans Aging Cohort (VACS) Index 
(18). Consistent with studies of the general population, our data also suggest that pre-frailty 
in the HIV population is an intermediary in the spectrum of progression from non-frailty to 
frailty (3, 5) and that it is a state more modestly associated with frailty-related factors such 
as medical and psychosocial comorbidity (6). In this cross-sectional analysis, several factors 
were associated with pre-frailty/frailty: high D-dimer, history of ADI, hepatitis C 
seropositivity, and greater current depression score. White non-Hispanic participants were 
less likely to be pre-frail/frail.
D-dimer, a marker of activation of the coagulation cascade has been associated with incident 
age-related frailty (19). A low-grade, chronic and systemic pro-inflammatory state 
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negatively impacts multiple organ systems (11) and is a hallmark of aging, age-related 
frailty, HIV disease, and increasingly, HIV-related frailty (9). Longitudinal analyses of 
changes in biomarker levels during progression to frailty would be necessary to further 
elucidate the role of chronic inflammation and activation of the coagulation cascade in the 
development of frailty.
Our finding that history of ADI was associated with prevalent pre-frailty/frailty is consistent 
with other studies (6-8). A history of ADI (clinical immunodeficiency) may confer an 
increased risk of developing pre-frailty or frailty when, additional physiological insults 
ultimately accumulate due to aging, sociodemographic factors, lifestyle behaviors, 
comorbidities, and/or ongoing chronic inflammation (20). Furthermore, the additive effect of 
the number of past ADI may also increase the risk of becoming pre-frail/frail (6). Future 
longitudinal studies on prevention of ADI to ameliorate risk for pre-frailty/frailty might 
underscore the importance of earlier HIV diagnosis, treatment, and retention in care (20, 21).
Consistent with findings in the Women's Interagency Health Study, wherein, Hispanic HIV-
infected women had significantly weaker grip strength than women from other racial/ethnic 
groups (8), we demonstrated a higher pre-frailty/frailty prevalence among persons of non-
white race/ethnicity. Older HIV-uninfected black and Hispanic adults have a higher frailty 
prevalence (5, 22) and over classification of racial/ethnic minorities as pre-frail or frail could 
occur since the standardized height and BMI in frailty assessment criteria fail to account for 
normal differences in the range of these values among different racial/ethnic groups (16). 
However, differences in other factors associated with racial/ethnic disparities, such as 
poverty, unemployment, health-care utilization, comorbidity, HIV testing, retention in HIV-
related care and antiretroviral adherence (21, 23, 24), may have contributed to our findings.
Greater current depression scores have been consistently reported in numerous cross-
sectional studies of age and HIV-related frailty (2, 4-6, 9). Depression may influence self-
reporting of exhaustion and physical inactivity due to an overlap of symptoms with frailty. 
Furthermore, both depression and frailty are associated with racial/ethnic minorities, 
medical and psychosocial comorbidity, advanced HIV disease, hepatitis C co-infection and 
increased risk of death (24-27). However, depression can negatively impact motor function 
and contribute to disability (27) and depressive symptoms were strongly associated with 
incident frailty in older HIV-uninfected women in the Women's Health Initiative Study (5). 
Lastly, a study exploring the relationship between the constructs of depression (as defined by 
the Diagnostic Interview Schedule) and frailty showed that these are distinct but still 
overlapping syndromes (28). If one considers depression and frailty to be interrelated, then 
identification of depressive symptoms is imperative in the assessment of frailty state. 
Effective management of depression in the HIV-outpatient care setting is gaining 
prominence (29) and its impact on frailty states should be studied.
Hepatitis C seropositivity, a marker for a viral infection, that like HIV infection is associated 
with pro-inflammatory, psychiatric, psychosocial, and multisystem comorbidity (30-32), was 
also associated with frailty among HIV-infected men who have sex with men (33). 
Approximately a quarter of HIV-infected individuals in Europe and USA are Hepatitis 
C/HIV co-infected and at increased risk of cirrhosis, HIV-related disease, and overall 
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mortality (32). Persons with co-infection may be at increased risk for pre-frailty and frailty 
as well and effective treatment of this co-infection to prevent pre-frailty or frailty warrants 
consideration.
Our analysis present some limitations. The low prevalence of frailty in this cohort likely 
reduced our capacity to robustly test for and detect associations. We also did not collect data 
on disability. We combined the categories of pre-frail and frail in an effort to increase our 
statistical power. Some nuances may have been lost on subsequent analyses of this combined 
group; for readers’ reference we presented the data in table 1 stratified by all three groups, 
with p-values calculated using alternative statistical analysis. Missing data may have further 
limited analysis. We obtained initial frailty assessment data up to six years after study 
enrollment and can only make inferences based on our retrospective examination of 
longitudinal data and biomarker results. Lastly, we analyzed data from a contemporary, 
predominantly male population and our findings may not be generalizable to other HIV-
infected populations in the United States or elsewhere.
In conclusion, pre-frailty and frailty were prevalent in our cohort of HIV-infected adults 
receiving contemporary cART and was associated with unemployment, even among persons 
<50 years. Our analysis that included sociodemographic, clinical, and biomarker data 
corroborates the complex multifactorial associations with this syndrome. Furthermore, our 
data support the concept of pre-frailty as an intermediate state in the spectrum from non-
frailty through frailty that may represent a population of persons most likely to benefit from 
prevention strategies as well as depression screening.
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Non-frail, pre-frail* and frail SUN study participants by age
*excluding 10 participants with 1-2 frailty criteria but missing additional data such that they 
could not be assigned pre-frailty or frailty status with certainty.
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Table 1
Characteristics of SUN study participants by frailty status
Characteristic Non-frail (n =176) Pre-frail* (n =121) Frail (n =15) p-value
Demographics and behaviors
Age, years† 46 (40-52) 48 (43-54) 53 (45-54) 0.03
Male sex 149 (85%) 86 (71%) 13 (87%) 0.01
Race <0.001
 White, non-Hispanic 119 (68%) 57 (47%) 6 (40%)
 Black, non-Hispanic 38 (22%) 47 (39%) 6 (40%)
 Hispanic 15 (9%) 13 (11%) 3 (20%)
 Other/unknown 4 (2%) 4 (3%) 0
Current unemployment, n =311 48 (29%) 63 (52%) 13 (87%) <0.001
Long-term unemployment, n =265 29 (19%) 44 (46%) 9 (82%) <0.001
Current tobacco use 50 (29%) 53 (44%) 7 (47%) 0.02
Ever tobacco use 98 (57%) 78 (65%) 13 (87%) 0.03
Alcohol use last 30 days, n =311 123 (74%) 73 (60%) 5 (33%) 0.001
No. of days alcohol used per month†, n =311 3 (0-8) 2 (0-6) 0 (0-1) 0.006
Long-term alcohol use 137 (78%) 73 (60%) 5 (38%) 0.001
Past physical inactivity 2 (1%) 9 (7%) 7 (47%) <0.001
Perception of general health
Current response on study†, n =301 very good (excellent-good) good (very good-good) fair (good-fair) <0.001
 Excellent 42 (24%) 9 (7%) 0
 Good 29 (17%) 41 (34%) 5 (33%)
 Fair 8 (5%) 22 (20%) 5 (33%)
 Poor 1 (1%) 6 (6%) 3 (20%)
Past responses on study †, n =309 very good (very good-good) good (very good-good) fair (good-fair) <0.001
 Excellent 37 (21%) 11 (9%) 0
 Very good 93 (53%) 33 (28%) 1 (7%)
 Good 35 (20%) 52 (43%) 3 (21%)
 Fair 9 (6%) 21 (18%) 10 (72%)
 Poor 1 (1%) 3 (3%) 0
Co-morbidities
Body mass index, kg/m2 † 26.9 (24.2-30.6) 26.1 (22.9-29.6) 26.1 (23.0-29.8) 0.32
 Obese BMI 26% 22% 27% 0.91
 Underweight BMI 1% 3% 4% 0.09
Hepatitis C seropositivity 10 (6%) 24 (20%) 5 (33%) 0.001
Active hepatitis B nfection 6 (1%) 3 (3%) 2 (13%) 0.08
Current depression score†, n=306 3 (0-5) 6 (2-11) 8 (4-10) <0.001
Past depression score†, n=255 3 (1-7) 5 (3-10) 7 (3-9) <0.001
Hemoglobin, g/L† 15.1 (14.4-15.9) 14.3 (13.0-15.3) 14.6 (13.1-15.6) <0.001
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Characteristic Non-frail (n =176) Pre-frail* (n =121) Frail (n =15) p-value
Creatinine, mg/dL† 1.0 (0.9-1.1) 0.9 (0.8-1.1) 1.0 (0.9-1.4) <0.001
 eGFR <60mL/min/1.73m2, n =258 3% 4% 30% <0.001
Current STD, n=312 14 (8%) 4 (3%) 0 (0%) 0.13
Ever STD, n =266 56 (32%) 28 (29%) 0 (0%) 0.02
HIV-related factors
Time since HIV diagnosis, years† 9.4 (6.7-12.8) 11.8 (8.1-14.4) 10.4 (7.4-12.1) 0.03
History of ADI 26 (15%) 38 (31%) 8 (53%) < 0.001
Current cART 166 (94%) 112 (96%) 15 (100%) 0.58
Total time on cART, years† 7.5 (5.6-10.2) 8.2 (5.9-10.8) 6.8 (5.9-9.7) 0.7
CD4+ cell count, cells/mm3†
 Nadir 209 (100-295) 149 (45-257) 154 (70-175) 0.04
 Current 649 (470-813) 619 (418-795) 641 (460-943) 0.87
Viral suppression, n =203 121 (94%) 66 (99%) 8 (89%) 0.13
Biomarkers, median (IQR)
hs-CRP, mg/L 1.6 (0.8-3.3) 2.0 (0.9-4.2) 3.5 (0.9-7.6) 0.91
TNF-α, pg/mL, n=285 13.0 (10.3-18.9) 13.7 (11.2-24.4) 15.1 (10.1-339.0) < 0.001
IL-6, pg/mL, n=288 2.9 (2.0-5.0) 3.0 (2.0-6.5) 9.2 (2.1-4641.5) < 0.001
D-dimer, µg/L 0.11 (0.04-0.23) 0.14 (0.06-0.27) 0.20 (0.10-0.45) 0.001
sCD14, ng/mL‡ 1136.5 ± 24.0 1233.6 ± 33.8 1326.7 ± 91.5 0.06
Lipoprotein A, mg/mL 10.0 (4.0-30.0) 17.0 (6.0-45.0) 13.0 (6.0-33.0) 0.1
25-hydroxy vitamin D, ng/mL‡ 25.4 ± 0.9 21.4 ± 1.1 21.8 ± 3.5 0.07
Comparison of all three groups.
*
Excluding 10 persons who had 1-2 frailty criteria but could not be definitely assigned pre-frailty or frailty status due to missing values at the 
defining variables.
†
median, (interquartile range, IQR),
‡
mean ± standard error. ADI, AIDS-defining illness; cART, combination antiretroviral therapy; eGFR, estimated glomerular filtration rate; hs-CRP, 
high-sensitivity C-reactive protein; IL-6, interleukin-6; sCD14, soluble CD14; STD, sexually transmitted diseases; TNF-α, tumor necrosis factor-α.
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Table 2
Prevalence of individual frailty criteria among SUN study participants with complete data 
available
Frailty criteria Pre-frail* (n=121) Frail (n=15)
Unintentional weight loss 13 (11%) 1 (7%)
More than 10 pounds or ≥5% of weight loss occurred during the last year.
Physical inactivity 35 (29%) 15 (100%)
Participants answering “3” when asked whether their health limits vigorous activities (eg running, lifting heavy objects, participating in 
strenuous sports (1 = not at all, 2 = a little, or 3 = a lot).
Exhaustion 76 (63%) 11 (73%)
Participants answering 2 or 3 to either one of two statements – How often in the last week have you felt that: (a) everything you did was an 
effort or (b) I could not ‘get going’. 0 = rarely (< 1 day), 1 = some of the time (1-2 days), 2 = occasionally (3-4 days) or 3 = most of the time 
(5-7 days)
Weak grip strength 9 (7%) 11 (73%)
Strength, kg, median (IQR) 36 (29-44) 29 (23-39)
Cut-points according to BMI:
M: ≤24 kg/m2 ≤29 kg; 24.1-26.0 kg/m2 ≤30 kg; 26.1-28.0 kg/m2 ≤30 kg; >28 kg/m2 ≤32 kg.
W: <23 kg/m2<17 kg; 23.1-26.0 kg/m2 <17.3 kg; 26.1-29.0 kg/m2 <18 kg; >29 kg/m2<21 kg.
Slow walking speed (n=121) 20 (17%) 7 (54%)
Time, seconds, median (IQR) 4 (3-5) 8 (4-9)
Cut-points according to height:
M: ≤173 cm ≥7 sec; >173 cm ≥6 sec.
W: ≤159 cm ≥7 sec; >159 cm ≥6 sec.
Grip strength was determined from the average of three measurements of the dominant hand using a dynamometer (1). Walking was measured at 
usual pace over a 15-foot track (average of 2 trials) (1).
*
Excluding 10 persons who had 1-2 frailty criteria but could not be definitely assigned pre-frailty or frailty status due to missing values at the 
defining variables. M, men; W, women
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